Author:
Addo S,Yates R A,Laight A
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356: 881–887
2. Bilmoria MM, Jordan VC, Morrow M (1996) Additional benefits of tamoxifen for postmenopausal patients. In Tamoxifen a guide for clinicians and patients Jordan VC (ed) pp 75–89 Huntington NY: PRR Inc
3. Chlebowski R, Collyar DE, Somerfield MR, Pfister DG (1999) American Society of Clinical Oncology Technology. Assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17: 1939–1955
4. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C et al (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408–414
5. Dukes M, Miller D, Wakeling AE, Waterton JC (1992) Antiuterotrophic effects of a pure antioestrogen, ICI 182780; magnetic resonance imaging of the uterus in ovariectomised monkeys. J Endocrinol 135: 239–247
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献